5.09
-0.01(-0.20%)
Currency In USD
| Previous Close | 5.1 |
| Open | 5.09 |
| Day High | 5.15 |
| Day Low | 5 |
| 52-Week High | 7.54 |
| 52-Week Low | 3.93 |
| Volume | 749,470 |
| Average Volume | 1.73M |
| Market Cap | 254.5M |
| PE | 4.21 |
| EPS | 1.21 |
| Moving Average 50 Days | 4.9 |
| Moving Average 200 Days | 5.66 |
| Change | -0.01 |
If you invested $1000 in Abeona Therapeutics Inc. (ABEO) 10 years ago, it would be worth $69.02 as of January 14, 2026 at a share price of $5.09. Whereas If you bought $1000 worth of Abeona Therapeutics Inc. (ABEO) shares 5 years ago, it would be worth $102.83 as of January 14, 2026 at a share price of $5.09.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
GlobeNewswire Inc.
Dec 15, 2025 12:30 PM GMT
CLEVELAND, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the appointment of Mohamad Tabrizi, M.S., M.B.A., as Senior Vice President, Chief Business Officer (CBO). In this role, Mr. Tabrizi will lead the C
Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
GlobeNewswire Inc.
Dec 11, 2025 12:30 PM GMT
CLEVELAND, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced activation of The University of Texas Medical Branch (UTMB) in Galveston, Texas, as the newest Qualified Treatment Center (QTC) for the administrat
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
GlobeNewswire Inc.
Dec 08, 2025 12:30 PM GMT
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, autologous gene therapy for treat